ArticleRSC advances2025
Light-triggered degradable bridged polysilsesquioxane nanoplatforms for spatiotemporally controlled drug release.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing stimuli-responsive nanoplatforms is a promising strategy for controlling the release of targeted molecules. In this study, nitrobenzyl ester was chosen as a photoresponsive moiety to functionalize an organic bridged linker, facilitating the synthesis of a photoresponsive silane, namely 2-nitro-1,3-phenyl bis(methylene mercaptoacetate ester) bridged trimethoxysilane (SMS). Light-triggered degradable bridged polysilsesquioxane nanoparticles (SMPS) were achieved through hydrolysis-condensation reactions using SMS as a precursor in suspension polymerization. Upon irradiation at 365 nm for three hours, the particle size of SMPS decreased from 138 ± 20 nm to 103 ± 43 nm. The target molecule, evodiamine (Evo), was efficiently loaded onto SMPS through hydrophobic and electrostatic attractions, constructing a light-controlled release system, Evo@SMPS. The results of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.